Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of any NET
Evidence of re-treatment with lutetium-177 DOTATATE
* Documentation of initial treatment with a regimen of up to 4 doses of lutetium-177 DOTATATE, followed by evidence of progression, and then ≥1 subsequent dose of lutetium-177 DOTATATE
* Minimum of 6 months between the end of the initial treatment doses and the first re-treatment dose
You may not be if
\<18 years of age
Clareo Health | Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
